Pembrolizumab with chemotherapy for stage III lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a drug called pembrolizumab (an immunotherapy that helps your immune system fight cancer) combined with two chemotherapy drugs, without radiation. It is for people with stage III lung cancer that has not spread and has a high PD-L1 level. The goal is to see if this treatment can shrink or control the cancer better than the usual approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that has not spread to distant organs.
- Your cancer shows a high level of a protein called PD-L1 (at least 50%) on a test.
- You are not able to have surgery right now, and doctors think standard radiation plus chemo is the usual approach.
- You have not had any prior treatment for this cancer, like chemo or radiation.
- You are in generally good health and can take care of yourself (performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This trial tests whether pembrolizumab alone, or pembrolizumab plus chemotherapy, can treat stage IV non-small cell lung cancer. It may help shrink tumors and improve outcomes by boosting the immune system, with or without added chemotherapy.
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
Hear when a new Locally Advanced Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.